Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
842
mi
from 43215
Saint Petersburg, FL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
842
mi
from 43215
Saint Petersburg, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
297
mi
from 43215
Arlington Heights, IL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
297
mi
from 43215
Arlington Heights, IL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
394
mi
from 43215
Saint Louis, MO
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
394
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
343
mi
from 43215
Danville, PA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
343
mi
from 43215
Danville, PA
Click here to add this to my saved trials
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Georgetown Lombardi Comprehensive Cancer Center
328
mi
from 43215
Washington,
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Georgetown Lombardi Comprehensive Cancer Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
711
mi
from 43215
Gainesville, FL
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
711
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
874
mi
from 43215
Sarasota, FL
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
874
mi
from 43215
Sarasota, FL
Click here to add this to my saved trials
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
354
mi
from 43215
Durham, NC
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
331
mi
from 43215
Nashville, TN
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
331
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1653
mi
from 43215
Scottsdale, AZ
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1653
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
659
mi
from 43215
Fayetteville, AR
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
659
mi
from 43215
Fayetteville, AR
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
493
mi
from 43215
Lake Success, NY
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
493
mi
from 43215
Lake Success, NY
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1979
mi
from 43215
Beverly Hills, CA
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1979
mi
from 43215
Beverly Hills, CA
Click here to add this to my saved trials
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
542
mi
from 43215
Southington, CT
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
542
mi
from 43215
Southington, CT
Click here to add this to my saved trials
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
331
mi
from 43215
Nashville, TN
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
331
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
910
mi
from 43215
Dallas, TX
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1916
mi
from 43215
Highland, CA
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1916
mi
from 43215
Highland, CA
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
453
mi
from 43215
Morristown, NJ
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
453
mi
from 43215
Morristown, NJ
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
444
mi
from 43215
Somerville, NJ
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
444
mi
from 43215
Somerville, NJ
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
501
mi
from 43215
Germantown, TN
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
501
mi
from 43215
Germantown, TN
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
991
mi
from 43215
Houston, TX
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
590
mi
from 43215
Burlington, VT
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
590
mi
from 43215
Burlington, VT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1655
mi
from 43215
Chandler, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1655
mi
from 43215
Chandler, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1648
mi
from 43215
Gilbert, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1648
mi
from 43215
Gilbert, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1650
mi
from 43215
Mesa, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1650
mi
from 43215
Mesa, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1653
mi
from 43215
Scottsdale, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1653
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1964
mi
from 43215
Pasadena, CA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1964
mi
from 43215
Pasadena, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2042
mi
from 43215
Santa Barbara, CA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2042
mi
from 43215
Santa Barbara, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1161
mi
from 43215
Colorado Springs, CO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1161
mi
from 43215
Colorado Springs, CO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1162
mi
from 43215
Denver, CO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
786
mi
from 43215
Altamonte Springs, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
786
mi
from 43215
Altamonte Springs, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
993
mi
from 43215
Miami, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
747
mi
from 43215
Ocala, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
747
mi
from 43215
Ocala, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
792
mi
from 43215
Orlando, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
792
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
286
mi
from 43215
Niles, IL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
286
mi
from 43215
Niles, IL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
205
mi
from 43215
Lafayette, IN
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
205
mi
from 43215
Lafayette, IN
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
569
mi
from 43215
Ames, IA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
569
mi
from 43215
Ames, IA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
798
mi
from 43215
New Orleans, LA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
798
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
502
mi
from 43215
Jefferson City, MO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
502
mi
from 43215
Jefferson City, MO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
721
mi
from 43215
Lincoln, NE
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
721
mi
from 43215
Lincoln, NE
Click here to add this to my saved trials